Prelude Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Prelude Capital Management's FDMT Position: Q3 2026 in Review
Prelude Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q3 2026, closing a stake of 11,040 shares — an estimated $147K sold.
Prelude Capital Management first reported a position in FDMT in Q4 2022 and held it in 7 quarters. The position peaked at $281K in Q4 2022. 162 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Prelude Capital Management reported no remaining 4D Molecular Therapeutics position as of Q3 2026 after selling out during the quarter.
- Prelude Capital Management sold 11,040 4D Molecular Therapeutics shares in Q3 2026, an estimated $147K.
- Prelude Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 7 quarters.
- Prelude Capital Management's 4D Molecular Therapeutics position peaked at $281K in Q4 2022.
- 162 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.